Literature DB >> 8978772

Reassignment of MYCL1 to human chromosome 1p34.3 by fluorescence in situ hybridization.

F Speleman1, G Van Camp, N Van Roy.   

Abstract

MYCL1 has been previously mapped to 1p32. This position was in contradiction with our mapping data of 1p deletions in neuroblastoma cell lines. Using FISH on high resolution R-banded chromosomes with a YAC clone for MYCL1 we were able to reassign the gene to subband 1p34.3. This new map position is of importance for the establishment of an integrated map for chromosome 1 and the search for disease genes in this region.

Entities:  

Mesh:

Year:  1996        PMID: 8978772     DOI: 10.1159/000134185

Source DB:  PubMed          Journal:  Cytogenet Cell Genet        ISSN: 0301-0171


  5 in total

Review 1.  Cytogenetic analysis of a malignant triton tumour by comparative genomic hybridization (CGH) and review of the literature.

Authors:  Dimitrios Koutsimpelas; Jürgen Brieger; Ulf Heinrich; Michael Torzewski; Clemens Sommer; Wolf J Mann
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-06-05       Impact factor: 2.503

2.  Assignment of the muscle-eye-brain disease gene to 1p32-p34 by linkage analysis and homozygosity mapping.

Authors:  B Cormand; K Avela; H Pihko; P Santavuori; B Talim; H Topaloglu; A de la Chapelle; A E Lehesjoki
Journal:  Am J Hum Genet       Date:  1999-01       Impact factor: 11.025

3.  Loss of heterozygosity at chromosome 1p in different solid human tumours: association with survival.

Authors:  G Ragnarsson; G Eiriksdottir; J T Johannsdottir; J G Jonasson; V Egilsson; S Ingvarsson
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

4.  Genomic and gene expression profiling of minute alterations of chromosome arm 1p in small-cell lung carcinoma cells.

Authors:  L-J Henderson; B P Coe; E H L Lee; L Girard; A F Gazdar; J D Minna; S Lam; C MacAulay; W L Lam
Journal:  Br J Cancer       Date:  2005-04-25       Impact factor: 7.640

5.  Antimyeloma activity of bromodomain inhibitors on the human myeloma cell line U266 by downregulation of MYCL.

Authors:  Kazuhito Suzuki; Kouhei Yamamoto; Yasuhiro Arakawa; Hisashi Yamada; Keisuke Aiba; Masanobu Kitagawa
Journal:  Anticancer Drugs       Date:  2016-09       Impact factor: 2.248

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.